| Literature DB >> 35647264 |
Oluwasayo Peter Abodunrin1, Olayinka Fisayo Onifade2, Abayomi Emmanuel Adegboyega3.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a pandemic cause of Corona Virus Disease (COVID-19), that has claimed numerous human lives across the globe. Main protease being the active protein of SARS-CoV-2 requires urgent mitigating effect against the spread of the virus. The therapeutic roles of the active compounds present in ten typical African medicinal plants were investigated in this study. Five active compounds Curcuma longa (Curcumin and Bisdethoxy curcumin), Garcinia kola (kolaviron), Zingiber officinale (Gingerol) and Vernonia amygdalina (Artemisinin) were selected and docked against Main protease through receptor grid generation, protein ligand docking, receptor ligand complex pharmacophore and binding free energy. The results obtained revealed Curcumin had the highest binding score of -8.628 kcal/mol while artermisinin presented the least with -4.123 kcal/mol. The outcome of the pharmacokinetic prediction in this study revealed high transport capacity across the gastrointestinal tract and high blood brain barrier permeability for curcumin, bisdemethoxy curcumin, gingerol and artemisinin. The exemption is gingerol with low LD50 value (250 mg/kg), the LD50 of all active compounds ranged from 2000 to 4228 mg/kg. Adsorption, distribution, metabolism, excretion and toxicity (ADMET) properties exhibited by all compounds portrayed them as non-hepatotoxic, non-cytotoxic, non-mutagenic and non-carcinogenic. The active compounds exhibited drug-likeness features against Main protease of Covid-19.Entities:
Keywords: Active compounds; Binding free energy; COVID-19; Main protease; Molecular docking; Pharmacophore
Year: 2022 PMID: 35647264 PMCID: PMC9125996 DOI: 10.1016/j.imu.2022.100964
Source DB: PubMed Journal: Inform Med Unlocked ISSN: 2352-9148
Fig. 12D Structures of active compound present in medicinal plants.
The docking score (kcal/mol) of the active compound of medicinal plants against main proteinase of SARS-CoV-2.
| Active compound | Main proteinase of SARS-CoV-2 | PubChem ID |
|---|---|---|
| Curcumin | −8.628 | 969516 |
| Kolaviron | −7.027 | 155169 |
| (1s,2s)-2-({n-[(Benzyloxy)carbonyl]-L-Leucyl}amino)-1-Hydroxy-3-[(3s)-2-Oxopyrrolidin-3-Yl]propane-1-Sulfonic Acid | −6.541 | 118737648 |
| Bis-demethoxycurcumin | −4.975 | 5315472 |
| Gingerol | −4.252 | 442793 |
| Artemisinin | −4.123 | 68827 |
| Nimbic acid | −3.965 | 25446 |
| Thymoquinone | −3.931 | 10281 |
| Paradol | −3.924 | 94378 |
| Nimbolide | −3.883 | 12313376 |
| Ibuprofen | −3.727 | 3672 |
| Geraniol | −3.42 | 637566 |
| Beta-Pinene | −3.188 | 14896 |
| Citral | −3.061 | 638011 |
| Limonene | −2.9 | 22311 |
| Allicin | −2.236 | 65036 |
| Alpha-Pinene | 6654 |
Fig. 2a3D representations of SARS-CoV-2 3C-like Protease-kolaviron.
Fig. 2b2D and 3D representations of SARS-CoV-2 3C-like Protease-curcumin.
Fig. 2c2D and 3D representations of SARS-CoV-2 3C-like Protease-Bisdemethoxycurcumin.
Fig. 2d2D and 3D representations of SARS-CoV-2 3C-like Protease-Artemisinin.
Fig. 2e2D and 3D representations of SARS-CoV-2 3C-like Protease-Gingerol.
Fig. 2f2D and 3D representations of SARS-CoV-2 3C-like Protease-standard inhibitor.
SwissADMET prediction outputs of selected active compounds.
| AC | Molecular weight | Mean logp (0–3) | Silicos-IT Log SW (−0.7 to +6.0) | Silicos-IT class | Lipinski violations (>500 g/mol) | Veber violations (<140 Å2) | Bioavailability Score (100%) |
|---|---|---|---|---|---|---|---|
| A | 368.38 | 1.47 | −4.45 | MS | 0 | 0 | 0.55 |
| B | 588.52 | −0.48 | −5.76 | MS | 3 | 1 | 0.17 |
| C | 308.33 | 2.13 | −4.23 | MS | 0 | 0 | 0.55 |
| D | 294.39 | 2.14 | −4.58 | MS | 0 | 0 | 0.55 |
| E | 282.33 | 2.62 | −2.03 | S | 0 | 0 | 0.55 |
A = Curcumin, B=Kolaviron, C=Bisdemethoxycurcumin, D = Gingerol, E = Artemisinin, AC = Active compound; S=Soluble; MS = Moderately Soluble.
Pharmacokinetics prediction output of selected active compounds.
| AC | GI A | BBBP | Pgp | CYP1A2I | CYP2C19I | CYP2C9I | CYP2D6I | CYP3A4I |
|---|---|---|---|---|---|---|---|---|
| A | High | No | No | No | No | Yes | No | Yes |
| B | Low | No | No | No | No | Yes | No | Yes |
| C | High | Yes | No | Yes | No | Yes | No | Yes |
| D | High | Yes | No | Yes | No | No | No | No |
| E | High | Yes | No | Yes | No | No | No | No |
A = Curcumin; B=Kolaviron; C=Bisdemethoxy curcumin; D = Gingerol; E = Artemisinin AC = Active compound; GIA = GI Absorption; BBBBBB permeant; Pgp = Pgp substrate; CYP1A2I = CYP1A2 inhibitor; CYP2C19I = CYP2C19 inhibitor; CYP2C9I = CYP2C9 inhibitor; CYP2D6I = CYP2D6 inhibitor; CYP3A4I = CYP3A4 inhibitor.
Protoxll-predicated toxicity profile of selected active compound.
| AC | H T | C T | IT | MT | CT | LD50 (mg/kg) | PTC |
|---|---|---|---|---|---|---|---|
| A | Inactive | Inactive | Inactive | Inactive | Inactive | 2000 | 4 |
| B | Inactive | Inactive | Inactive | Inactive | Inactive | 2000 | 4 |
| C | Inactive | Inactive | Active | Inactive | Inactive | 2560 | 5 |
| D | Inactive | Inactive | Inactive | Inactive | Inactive | 250 | 3 |
| E | Inactive | Inactive | Inactive | Inactive | Inactive | 4228 | 5 |
A = Curcumin; B=Kolaviron; C-Bisdemethoxy curcumin, D-Gingerol, E− Arteminsinin
HT=Hepatotoxicity; CT=Carcinogenicity; IT=Immunotoxicity, CT=Cytotoxicity; PTC=Predicted Toxicity Class.
Binding free energy calculations of top five hit compounds against main protease.
| AC | ΔGBind | ΔG_Coulomb | ΔG_Covalent | ΔG_Hbond | ΔG_Lipo | ΔG_Packing | ΔG_vdWg |
|---|---|---|---|---|---|---|---|
| A | −59.50 | −36.72 | 7.61 | −2.49 | −17.82 | −0.81 | −41.05 |
| B | −61.33 | −41.99 | 6.91 | −3.84 | −7.34 | −4.52 | −39.90 |
| C | −42.99 | 28.22 | 6.75 | −1.32 | −20.49 | −0.34 | −53.66 |
| D | −52.87 | −28.69 | 4.06 | −2.43 | −13.31 | −1.33 | −29.12 |
| E | −45.10 | −17.89 | 7.47 | −1.62 | −16.75 | −0.51 | −33.12 |
| F | −22.12 | 1.34 | −0.01 | −1.13 | −7.20 | 0 | −26.67 |
AC-Active compound A-Curcumin B-Kolaviron C- (1s,2s)-2-({n-[(Benzyloxy)carbonyl]-L-Leucyl}amino)-1-Hydroxy-3-[(3s)-2-Oxopyrrolidin-3-Yl]propane-1-Sulfonic Acid D-Bis Demethoxy curcumin E-Gingerol F-Artemisinin.
MM-GBSA free energy (kcal/mol) of binding.
Contribution to the MM-GBSA free energy of binding (kcal/mol) from the Coulomb energy.
Contribution to the MM-GBSA free energy of binding (kcal/mol) from hydrogen bonding.
Contribution to the MM-GBSA free energy of binding (kcal/mol) from lipophilic binding.
Contribution to the MM-GBSA free energy of binding (kcal/mol) from packing binding.
Contribution to the MM-GBSA free energy of binding (kcal/mol) from solvent GB binding.
Fig. 3Pharmacophore models of kolaviron, curcumin, Bisdemethoxy curcumin and (1s,2s)-2-({n-[(Benzyloxy)carbonyl]-L-Leucyl}amino)-1-Hydroxy-3-[(3s)-2-Oxopyrrolidin-3-Yl]propane-1-Sulfonic Acid on SARS-CoV-2 Main proteinase.
Fig. 4Binding free energy MMGBSA dG Bind (ΔGbind) versus docking score (kcal/mol).